Antidepressant and anxiolytic efficacy and tolerability of agomelatine in the treatment of depression after COVID-19 in daily clinical practice (non-interventional study TELESPHOR) DOI Creative Commons
Константин Быков, А Н Боголепова,

Denis P. Morozov

и другие.

Neurology neuropsychiatry Psychosomatics, Год журнала: 2024, Номер 16(6), С. 61 - 70

Опубликована: Дек. 17, 2024

Depression and anxiety are among the most common disorders observed in patients after COVID-19 coronavirus infection. Objective : to evaluate antidepressant efficacy tolerability of agomelatine with a depressive episode (DE) infection everyday clinical practice. Material methods . The multicenter observational study TELESPHOR included outpatients aged 18 65 years who developed DE (Hamilton Rating Scale (HAMD-17) score 8–24) within 3 months resolution laboratory-confirmed started monotherapy agomelatine. Patients were assessed at enrolment subsequently weeks 2, 4 8 observation period. primary endpoint was change HAMD-17 scores by week taking as an antidepressant. main secondary outcome variables dynamics for items 10 (psychic anxiety) 11 (somatic scale, proportion responders remitters (according scale) impact on quality life (QOL) according SF-36 questionnaire. each visit. Data from all participated took least once safety analysis. final analysis data 103 patients, including 73 women (70.9%). Results Treatment associated significant improvement depression severity: mean total decreased statistically significantly 16.3±4.7 inclusion 13.7±4.5, 9.5±4.9 5.4±3.6 points – 2.6±3.3, 6.7±5.3 10.9±4.9 points, respectively, compared baseline (p<0.0001 time points). average item scale also 1.4±0.9 1.3±0.8 0.5±0.6 0.6±0.6 eighth (p<0.0001). indicators scales physical functioning mental health questionnaire improved initial values 39.7±8.4 50.5±5.7 (p<0.0001) 37.3±8.6 58.7±6.9 week. 81.4 %, 71.6%. Agomelatine well tolerated during entire No adverse events recorded that led discontinuation drug. One patient showed inefficacy treatment, so he discontinued participation study. Conclusion treatment is characterized anxiolytic efficacy, QOL good tolerability.

Язык: Английский

SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors DOI Creative Commons
Emad Behboudi, Seyed Nooreddin Faraji, Gholamreza Daryabor

и другие.

Heliyon, Год журнала: 2024, Номер 10(4), С. e26577 - e26577

Опубликована: Фев. 1, 2024

A critical step in the drug design for SARS-CoV-2 is to discover its molecular targets. This study comprehensively reviewed mechanisms of SARS-CoV-2, exploring host cell tropism and interaction targets crucial entry. The findings revealed that beyond ACE2 as primary entry receptor, alternative receptors, co-receptors, several proteases such TMPRSS2, Furin, Cathepsin L, ADAM play roles virus subsequent pathogenesis. Additionally, displays various human organs due diverse receptors. review delves into intricate details proteases, involvement each organ. Polymorphisms receptor mutations spike or RBD region contribute emergence variants like Alpha, Beta, Gamma, Delta, Omicron, impacting pathogenicity SARS-CoV-2. challenge posed by raises questions about effectiveness existing vaccines drugs, necessitating consideration updates their formulations. In urgency these situations, repurposed drugs Camostat Mesylate Nafamostat emerge viable pharmaceutical options. Numerous are involved inhibiting receptors factors entry, with most discussed this review. conclusion, may provide valuable insights inform decisions therapeutic approaches.

Язык: Английский

Процитировано

10
COVID-19 mortality among selective serotonin reuptake inhibitor users—results from a nationwide cohort DOI Creative Commons
Marius Ahm Stauning,

Dogukan Jesper Gür,

Christian Torp‐Pedersen

и другие.

Clinical Microbiology and Infection, Год журнала: 2023, Номер 29(8), С. 1075 - 1082

Опубликована: Май 6, 2023

To examine differences in mortality and/or severe acute respiratory syndrome between selective serotonin reuptake inhibitor- (SSRI) users and non-SSRI up to 60 days after a positive SARS-CoV-2 real-time reverse transcription PCR test.Retrospective cohort study including all Danish residents above the age of eighteen with test from 26 February, 2020 5 October, 2021. The follow-up period was days. primary outcome all-cause mortality, secondary syndrome. Exposure interest SSRI use. Differences non-users were examined Cox regression.Altogether, 286,447 individuals identified, 7113 met criteria for had mean 50.4 years, 34% males. Non-SSRI 41.4 50% Similar vaccination frequency observed among two groups. Sertraline most commonly used SSRI, followed by citalopram escitalopram. We found 255 deaths (3.6%) 2872 (1.0%). use significantly associated increased hazard ratio 1.32 (95% confidence interval, 1.16 -1.50; p 0.015), even when adjusting age, sex, status, comorbidities.We higher comparing within test. Even considering possible residual confounding, effect intake seems highly unlikely. Our therefore speaks against hypothesis repurposing drugs COVID-19 treatment.

Язык: Английский

Процитировано

11
Is There such a Thing as Post-Viral Depression?: Implications for Precision Medicine DOI
Eun‐Sook Park, Chan Young Shin,

Se Jin Jeon

и другие.

Biomolecules & Therapeutics, Год журнала: 2024, Номер 32(6), С. 659 - 684

Опубликована: Окт. 21, 2024

Viral infections are increasingly recognized as triggers for depressive disorders, particularly following the SARS-CoV-2 pandemic and rise of long COVID. Viruses such Herpes Simplex Virus (HSV), Epstein-Barr (EBV), Cytomegalovirus (CMV), Human Immunodeficiency (HIV) linked to depression through complex neurobiological mechanisms. These include immune system dysregulation, chronic inflammation, neurotransmitter imbalances that affect brain function mood regulation. activation leads release pro-inflammatory cytokines, resulting in neuroinflammation associated symptoms. Furthermore, specific viruses can disrupt systems, including serotonin, dopamine, glutamate, all which essential stabilization. The unique interactions different with these systems underscore need virus-specific therapeutic approaches. Current broad-spectrum treatments often overlook precise pathways involved post-viral depression, reducing their efficacy. This review emphasizes understand create tailored interventions directly address effects induced by each type virus. may immunomodulatory target persistent antiviral therapies reduce viral load, or neuroprotective strategies restore balance. Precision medicine offers promising avenues effective management virus-induced providing patient-specific approaches biological mechanisms involved. By focusing on development targeted treatments, this aims pave way a new era psychiatric care fully addresses root causes infections.

Язык: Английский

Процитировано

3
Lithium and the risk of severe COVID-19 infection: A retrospective population-based register study DOI Creative Commons
Niklas Nilsson, Marie Bendix, Louise Öhlund

и другие.

Journal of Psychosomatic Research, Год журнала: 2025, Номер 190, С. 112053 - 112053

Опубликована: Фев. 13, 2025

Язык: Английский

Процитировано

0
The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID‐19 patients: A systematic review and meta‐analysis DOI
Dena Firouzabadi, Fatemeh Kheshti, Saeed Abdollahifard

и другие.

Health Science Reports, Год журнала: 2022, Номер 5(6)

Опубликована: Окт. 17, 2022

Abstract Background and Aim Due to the high social economic burden also mortality morbidity caused by coronavirus disease 2019 (COVID‐19) in past few years, researchers have aimed at finding solutions suppressing severity of infection. Recently, selective serotonin serotonin‐norepinephrine reuptake inhibitors (SSRI/SNRI) been investigated as an adjuvant treatment for COVID‐19. The aim current study was investigate impact SSRI/SNRIs on outcomes COVID‐19 patients. Methods In this systematic review meta‐analysis, a comprehensive search strategy consisting relevant words performed two PubMed, Scopus EMBASE libraries. Studies reporting effect SSRI and/or SNRI use patients' outcome were included. Hospitalization, mortality, hospitalization event, length hospital stay considered main study. Analysis carried out using Comprehensive Meta‐Analysis (CMA‐version 2) final data reported odds ratio (OR) 95% confidence interval (CI). Results Our led selection 9 articles including 15,287 fluvoxamine, fluoxetine, overall SSRI/SNRI patients 3, 2, 7 articles, respectively. results our analyses showed that these medications could significantly decrease (OR [CI]: 0.595 [0.467–0.758], 0.620 [0.469–0.821], 0.596 [0.437–0.813]). events not significant (OR: 0.240% CI: 0.041–1.4). Also, longer who administrated SSRIs. Conclusion According study's results, may be effective reducing patients, suggesting superiority fluvoxamine fluoxetine. safety profile affordable cost short‐term other reasons propose them beneficial preventing

Язык: Английский

Процитировано

13
Inhibitory effects of fluoxetine on the secretion of inflammatory mediators and JAK/STAT3 and JNK/TLR4 gene expression DOI Open Access
Hoda Mojiri-Forushani, Elham Khajehali, Maryam Adelipour

и другие.

Molecular Biology Reports, Год журнала: 2022, Номер 50(3), С. 2231 - 2241

Опубликована: Дек. 26, 2022

Язык: Английский

Процитировано

12
The effectiveness and tolerability of agomelatine in the treatment of depression after COVID-19 infection in Russian daily clinical practice (TELESPHOR study) DOI Open Access
В Э Медведев, А Н Боголепова,

Denis P. Morozov

и другие.

Authorea (Authorea), Год журнала: 2024, Номер unknown

Опубликована: Апрель 21, 2024

Aim : Affective disorders such as depression and anxiety are one of the most prevalent symptoms observed in patients following coronavirus disease 2019 (COVID-19). The aim TELESPHOR study was to evaluate antidepressant effectiveness tolerability agomelatine therapy daily clinical practice with major depressive episodes (MDE) post-COVID-19. Methods This multicenter, observational enrolled outpatients aged 18-65 years who experienced an MDE (17 item Hamilton Rating Scale for Depression [HAMD-17] total score 8-24) within 3 months laboratory confirmed SARS-CoV-2 infection had initiated treatment agomelatine. Study visits occurred at weeks 2, 4 8. primary outcome assessed by change HAMD-17 week Secondary outcomes included changes 10 (anxiety psychic) 11 somatic), proportion responders (≥50% decrease baseline HAMD-17) remitters (HAMD-17 ≤7 8), impact on quality life (QoL) (Short Form Survey [SF-36] questionnaire). Tolerability each visit. Results full analysis set comprised 103 whom 73 (70.9%) were women. Median age 45 years, past 81 (78.6%) mild 22 (21.4%) moderate COVID-19. mean time from onset inclusion 2.1±0.7 months. At entry, 55 (53.4%) 48 (46.6%) MDE. Agomelatine associated a significant improvement severity decreases compared 2.6±3.3, 6.7±5.3, 10.9±4.9 4, 8, respectively (P<0.0001 all). Significant reductions psychic somatic also observed. Mental physical components SF-36 significantly improved (P<0.0001). 81.4% 71.6%. well tolerated over 8-week follow-up. Conclusion Treatment rapid antidepressive anxiolytic effectiveness, QoL, good after

Язык: Английский

Процитировано

1
Die Bedeutung von Antidepressiva bei COVID-19 und Long-COVID – Ein Scoping-Review Update DOI
Udo Bonnet, Georg Juckel

Fortschritte der Neurologie · Psychiatrie, Год журнала: 2024, Номер unknown

Опубликована: Сен. 23, 2024

Introduction Preclinically, fluvoxamine and other antidepressants (AD) exerted antiviral anti-inflammatory properties also against SARS-COV-2. Therfore, It makes sense to test the clinical effect of AD COVID-19 Long COVID.

Язык: Английский

Процитировано

1
Duloxetine hydrochloride enteric-coated pellets in capsules with delayed release: formulation and evaluation DOI

Ramya Krishna Nakkala,

Balaji Maddiboyina,

Shanmukha Chakravarthi Bolisetti

и другие.

Smart Science, Год журнала: 2023, Номер 11(3), С. 434 - 446

Опубликована: Март 16, 2023

The primary purpose of this study is to develop and evaluate an effective reliable delayed-release dosage form Duloxetine hydrochloride enteric-coated pellets in capsules. dissolves acidic environment, yet maintain their enteric coating due the Wurster expansion process for Fluidized Bed Processor. Four distinct layers comprise pellets: a pharmaceutical layer, barrier on inert core pellets. A suspension layering approach protects environment from drug by it with layer composed hydroxyl propyl methyl cellulose phthalate HP55. We also determined bulk tapped densities, Hausner’s ratio, compressibility index, moisture content all formulations. produced are being evaluated in-vitro release tests using UV-Visible spectroscopy. zero-order model, first-order Higuchi’s square root equation, Hixson-Crowell, Korsemeyer peppas, Weibull model were used released kinetics models. Investigations FT-IR (infrared spectroscopy) still undertaken determine drug’s compatibility various excipients. Formulation ‘F7’ exhibited highest similarity factor 56.1. Stability conducted over three-month period under accelerated settings established that optimized formulation stable.

Язык: Английский

Процитировано

3
COVID-19 as a polymorphic inflammatory spectrum of diseases: a review with focus on the brain DOI Creative Commons
Siu Wa Tang,

Daiga M. Helmeste,

Brian E. Leonard

и другие.

Acta Neuropsychiatrica, Год журнала: 2023, Номер 35(5), С. 248 - 269

Опубликована: Март 2, 2023

Abstract There appear to be huge variations and aberrations in the reported data COVID-19 2 years now into pandemic. Conflicting exist at almost every level also epidemiological statistics across different regions. It is becoming clear that a polymorphic inflammatory spectrum of diseases, there wide range inflammation-related pathology symptoms those infected with virus. The host’s response appears determined by genetics, age, immune status, health status stage disease. interplay these factors may decide magnitude, duration, types pathology, prognosis disorders, whether neuropsychiatric disorders continue significant. Early successful management inflammation reduces morbidity mortality all stages COVID-19.

Язык: Английский

Процитировано

1